PASPALUM NOTATUM POLLEN: 60 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
60
Total FAERS Reports
0
Deaths Reported
0
Hospitalizations
60
As Primary/Secondary Suspect
ALK-Abello, Inc.
Manufacturer
Drug Class: Allergens [CS] · Manufacturer: ALK-Abello, Inc. ·
First Report: 20150318 · Latest Report: 20250604
What Are the Most Common PASPALUM NOTATUM POLLEN Side Effects?
#1 Most Reported
Urticaria
14 reports (23.3%)
#2 Most Reported
Throat irritation
12 reports (20.0%)
#3 Most Reported
Erythema
12 reports (20.0%)
All PASPALUM NOTATUM POLLEN Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Urticaria | 14 | 23.3% | 0 | 0 |
| Erythema | 12 | 20.0% | 0 | 0 |
| Throat irritation | 12 | 20.0% | 0 | 0 |
| Cough | 11 | 18.3% | 0 | 0 |
| Local reaction | 8 | 13.3% | 0 | 0 |
| Pruritus | 8 | 13.3% | 0 | 0 |
| Anaphylactic reaction | 7 | 11.7% | 0 | 0 |
| Injection site erythema | 6 | 10.0% | 0 | 0 |
| Injection site reaction | 6 | 10.0% | 0 | 0 |
| Wheezing | 6 | 10.0% | 0 | 0 |
| Chest discomfort | 5 | 8.3% | 0 | 0 |
| Dyspnoea | 5 | 8.3% | 0 | 0 |
| Flushing | 5 | 8.3% | 0 | 0 |
| Injection site urticaria | 5 | 8.3% | 0 | 0 |
Who Reports PASPALUM NOTATUM POLLEN Side Effects? Age & Gender Data
Gender: 57.4% female, 42.6% male. Average age: 38.0 years. Most reports from: US. View detailed demographics →
Is PASPALUM NOTATUM POLLEN Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2015 | 6 | 0 | 0 |
| 2016 | 27 | 0 | 0 |
| 2017 | 1 | 0 | 0 |
| 2018 | 5 | 0 | 0 |
| 2019 | 3 | 0 | 0 |
| 2020 | 2 | 0 | 0 |
| 2021 | 1 | 0 | 0 |
| 2022 | 1 | 0 | 0 |
| 2023 | 6 | 0 | 0 |
| 2025 | 1 | 0 | 0 |
What Is PASPALUM NOTATUM POLLEN Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 6 |
| Rhinitis allergic | 6 |
Other Drugs in Same Class: Allergens [CS]
Official FDA Label for PASPALUM NOTATUM POLLEN
Official prescribing information from the FDA-approved drug label.